Vitura Health (ASX:VIT) announced a binding commercial distribution agreement with MedReleaf Australia.
The partnership integrates MedReleaf's extensive product suite—which includes prominent brands like IndiMed, Aurora, and CraftPlant—into Vitura's established Canview platform and the nationwide network of Burleigh Heads Cannabis.
The collaboration marks a pivotal expansion for Vitura, providing MedReleaf with unprecedented access to the approximately 4,700 Australian pharmacies currently registered on the Canview system.
While the agreement contains no minimum purchase mandates, Vitura’s management estimates that the deal could eventually generate up to $15 million in additional annual revenue.
The projected growth remains contingent on market factors, including patient uptake and the evolving regulatory environment.
The announcement comes amidst a broader period of expansion for Vitura’s Specialty Clinics Division.
Following a 2024 joint venture with Flora Holdings, the company has been actively re-engaging a patient base of 30,000 individuals across physical clinics in Victoria, New South Wales, and Queensland.
By aligning with MedReleaf—a subsidiary of the Canadian giant Aurora Cannabis—Vitura aims to capitalise on the increasing demand for pharmaceutical-grade medicinal cannabis and modernised healthcare delivery, including telehealth and DVA-compliant services.
At the time of reporting, Vitura Health's share price was $0.042.